The Real World Evidence Conference in Germany was a key highlight of the Pricing & Reimbursement Summit Europe, bringing together leading experts, policymakers, and industry professionals to discuss the growing importance of real-world evidence (RWE) in healthcare decision-making. The event, held in Frankfurt, served as a vital platform for exploring the role of RWE in shaping pricing strategies, market access, and reimbursement policies across Europe.
The Growing Importance of Real-World Evidence
Real-world evidence has become an essential tool in the pharmaceutical and healthcare industries, providing valuable insights into treatment effectiveness, patient outcomes, and healthcare system efficiencies. As regulatory bodies and payers increasingly rely on RWE for pricing and reimbursement decisions, discussions at the Real World Evidence Conference in Germany focused on best practices, challenges, and innovative methodologies in data collection and analysis.
The event will feature a distinguished lineup of speakers, including:
- Varun Gupta, Director of Value and Access at Novartis, Switzerland
- Gustavo Olivera, HEOR Expert at Sanofi, France
- Erwin Bruninx, Managing Director at GrayFox ComV
- James Graveston, Director of Real World Evidence Solutions at Whyze Health
- Helen Chamberlain, Scientific Advisor for Data Access & Analytics at NICE, UK
- Agata Krasoń, Data Scientist at Roche
These experts will share insights on integrating RWE into pricing strategies, enhancing collaboration between industry and public research, and navigating the complexities of European reimbursement landscapes.
Key Discussions and Themes
The conference featured insightful sessions led by top experts, covering a range of crucial topics, including:
- The Role of RWE in Pricing and Market Access – Experts discussed how real-world data influences drug pricing strategies and supports value-based healthcare models.
- Regulatory and HTA Perspectives – Policymakers and regulatory professionals shared updates on the acceptance of RWE in health technology assessments (HTA) and reimbursement frameworks.
- Data Integration and AI in RWE – Presentations explored the integration of artificial intelligence and digital health technologies in improving real-world data analysis and utilization.
- Cross-Border Reimbursement Challenges – Panel discussions addressed differences in RWE adoption across European markets and strategies for harmonization.
Industry Experts and Networking Opportunities
The Real World Evidence Conference in Germany attracted a distinguished lineup of speakers, including representatives from pharmaceutical companies, regulatory agencies, and research institutions. Attendees had the opportunity to engage in interactive discussions, case study presentations, and networking sessions, fostering collaborations that drive advancements in real-world evidence applications.
The Real World Evidence Conference in Germany at the Pricing & Reimbursement Summit Europe underscored the critical role of RWE in shaping the future of healthcare. As the demand for real-world data-driven decisions continues to rise, industry stakeholders must work together to overcome challenges and maximize the potential of RWE in improving patient outcomes and healthcare sustainability.
For more information and to register for the summit at https://veridonglobal.com/events/evidence-360-rwe-pricing-reimbursement-summit-europe/evidance-360-registration/
For professionals involved in healthcare policy, market access, and drug development, staying informed about real-world evidence trends is essential. Events like these provide a valuable opportunity to gain insights, share expertise, and contribute to the evolving landscape of evidence-based healthcare decision-making.
